Why Vertex Pharmaceuticals Incorporated, Michael Kors Holdings, Ltd., and The ADT Corporation Are To
This is an exciting time for the planet Earth, as billions of people around the globe turn their attention to the world's most popular sport: something Americans decided to call soccer. Maybe all the excitement surrounding the beginning of the 2014 World Cup in Brazil is to blame for the lull on Wall Street today. Why get worked up about stocks when you can be serenaded by the sweet sound of deafening vuvuzelas? Investors in Vertex Pharmaceuticals Incorporated , Michael Kors Holdings, Ltd. , and The ADT Corporation certainly weren't worked up, as each stock finished as one of the worst in the S&P 500 Index . The S&P, for its part, added 1 point, or 0.1%, to end at 1,937.
Vertex Pharmaceuticals shed 8.7% after a pessimistic analyst report from Bernstein research. The biotech company, which sells treatments for hepatitis C and cystic fibrosis, will likely catch heat from shareholders if Phase 3 trials for its cystic fibrosis treatment don't paint an upbeat picture. Vertex Pharmaceuticals already markets a drug called Kalydeco in the EU and U.S., but the company's studying a combination of Kalydeco and another drug called VX-809 in hopes that the combo might be more effective. According to scientists at a cystic fibrosis conference in Sweden this weekend, those hopes are possibly misguided.
Shares of luxury fashion retailer Michael Kors lost 3.8% on Monday, ending as another notable laggard in the S&P 500. Michael Kors has been a lousy stock to bet against in the last year, as shares soared nearly 50% and the company continued to gobble up market share from industry big wigs like Coach. Now it looks like Kors has an up-and-coming rival of its own to worry about: Vince Holding, which just posted a 32% jump in sales in the first quarter as the company swung to a profit.
The last of the day's laggards, ADT Corporation, saw its stock fall 1.8% today. Revenue growth at the home security company has been precariously decelerating since 2011, when sales grew by 20%. Last year sales grew by just 2.5%. A rapidly changing industry in which newer, sexier entrants embracing things like do-it-yourself installation and smart energy management solutions are flipping the business on its head. ADT isn't exactly behind the curve; it's promoting ADT Pulse, which lets consumers remotely adjust their thermostats. That said, money talks, and ADT hasn't yet proved that it can execute on the concept emphatically enough for Wall Street to fall in love with it.
Are you ready for this $14.4 trillion revolution?
Have you ever dreamed of traveling back in time and telling your younger self to invest in Apple? Or to load up on Amazon.com at its IPO, and then just keep holding? We haven't mastered time travel, but there is a way to get out ahead of the next big thing. The secret is to find a small-cap "pure play" and then watch as the industry -- and your company -- enjoy those same explosive returns. Our team of equity analysts has identified one stock that's ready for stunning profits with the growth of a $14.4 trillion industry. You can't travel back in time, but you can set up your future. Click here for the whole story in our eye-opening report.
The article Why Vertex Pharmaceuticals Incorporated, Michael Kors Holdings, Ltd., and The ADT Corporation Are Today's 3 Worst Stocks originally appeared on Fool.com.John Divine owns shares of Apple and Michael Kors Holdings. You can follow him on Twitter, @divinebizkid , and on Motley Fool CAPS, @TMFDivine . The Motley Fool recommends Amazon.com, Apple, Coach, Michael Kors Holdings, and Vertex Pharmaceuticals and owns shares of Amazon.com, Apple, Coach, and Michael Kors Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.